CN101785718A - Biological peptide blood vessel stent - Google Patents
Biological peptide blood vessel stent Download PDFInfo
- Publication number
- CN101785718A CN101785718A CN 200910045840 CN200910045840A CN101785718A CN 101785718 A CN101785718 A CN 101785718A CN 200910045840 CN200910045840 CN 200910045840 CN 200910045840 A CN200910045840 A CN 200910045840A CN 101785718 A CN101785718 A CN 101785718A
- Authority
- CN
- China
- Prior art keywords
- blood vessel
- metal
- stent
- biological peptide
- vessel stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
Abstract
The invention provides a biological peptide blood vessel stent. A body structure of the biological peptide blood vessel stent is a stent with dug grooves, and comprises a plurality of groups of metal wave rods and metal connecting rods, wherein the metal wave rods a are in a wave shape, a grooves are dug on the metal wave rods, active medicine ingredients are stored in the grooves or holes, the middle parts of the metal connecting rods are in a U shape or an S shape, and both ends of the metal connecting rods are respectively connected with the bending parts of the two metal wave rods. The active medicine ingredients in the biological peptide blood vessel stent are antibodies and/or peptides using vWFA1/A3 as effect targets, and the antibodies and/or peptides are directly uploaded on a metal stent with grooves engraved on the surface in a physical mode for ensuring that after the embedment of the stent, the antibodies and/or peptides can be fast released to injured blood vessel walls to be fast saturated in the injured parts of the blood vessels, and the activation on blood platelets by exposed collagen through vWF is prevented, so the thrombosis and the later stage restenosis are inhabited.
Description
Technical field
The present invention relates to medical instruments field, relate in particular to a kind of intravascular stent of grooving, store anti-vWF associated antibodies and albumen in the groove of this support.
Background technology
It is the common method of treatment of coronary heart disease that support is implanted, but restenosis can take place blood vessel after often having considerable patient to understand implant frame.Vascular restenosis is a complex process, be broadly divided into 5 stages: (1) thrombosis phase, (2) inflammatory phase, (3) vascular smooth muscle cell proliferation phase, (4) substrate forms the phase, (5) blood vessel is reinvented the phase (Drug-Eluting Stents, Delayed Healing, AndHypersensitivity Reactions, R.Virmani, tctmdTM, April, 2006).In the support implantation process, because conduit friction and balloon expandable effect; the injured endodermis of blood vessel peels off near the diseased region; vascular tissue is exposed; therefore bring out blood coagulation and inflammatory reaction; blood coagulation and inflammatory reaction can discharge a series of somatomedin, cytokine and inflammatory factor, cause smooth muscle cell (transferring synthesis type to by shrinkage type) and substrate hyper-proliferative.These a series of processes be one connect each other, interactional organic process, wherein thrombosis can cause inflammation, inflammation can increase the weight of thrombosis, smooth muscle cell proliferation can cause extracellular matrix to increase, and the substrate increase can increase the weight of cell proliferation.The final result of this series reaction has caused vascular restenosis.
Drug stent (the Drug-Eluting-Stent that is used for the treatment of coronary heart disease in the market, DES), carried the medicine that can suppress smooth muscle proliferation, since listing, its effectiveness is obvious to all, and (Bare Metal Stent BMS) implants back blood vessel restenosis rate and dropped to 3%-6% from 20%-30% with bare metal stent, but safety issue comes out recently gradually, is subjected to many doctor/experts' query.The greatest problem that comes out at present is the advanced thrombus problem.Though the probability that the DES advanced thrombus takes place is very low, is lower than 1%, consequence may be fatal.For avoiding the thrombosis problem, patient must long-term (six months to 1 year, especial patient even lifelong) take anticoagulant, and this brings very big financial burden to patient, and might cause side effect such as hemorrhage.
In view of first generation DES has the problem that postpones injured blood vessel healing, " promoting healing (pro-healing) " becomes the target of DES.The product of this respect comparative maturity is the Genous support of Orbus-Neich, this rack surface is connected to anti-CD34 antibody fragment (Fab), behind the implantable intravascular, the antibody fragment that is grafted on rack surface can be with (the Endothelial Progenitor Cell of endothelium progenitor cell in the blood, EPC) capture, EPC is divided into mature endothelial cell rapidly, impels injured blood vessel healing.Do not have advanced thrombus problem (only taking 30 days antiplatelet drugs) but the clinical trial Follow-up results shows the Genous support, but effectiveness is not as first generation DES.Genous introduces antibody by the method for chemical graft at rack surface in addition, and efficient is low-cost high, and the antibody amount of introducing is limited, and only limits to rack surface, and other vast diseased regions still do not have antibody and cover, and influence endothelialization efficient.
From the mechanism of support implantation back blood vessel generation restenosis, it is a major reason that causes restenosis that injured blood vessel causes blood coagulation.In the support implantation process, balloon expandable or support are implanted and all can be caused the blood vessel wall endothelial tissue impaired, thereby cause the blood vessel wall collagen protein exposed.Under high shear stress (in coronary blood flow) condition, and blood medium vessels christmas factor (von Willebrand Factor, the collagen protein that incite somebody to action rapidly in A3 territory vWF) and blood vessel wall is exposed is in conjunction with (Biochemistry 1986; 25 (26): 8357-8361, Blood 1987; 70 (5): 1577-1583, J.Biol.Chem.1987; 262 (28): 13835-13841), the vWF that is combined in collagen protein under effect under the high shear stress, its A1 territory again rapidly and platelet surface receptor GPIb/IX/V combination (Blood 1985; 65 (1): 85-90, Blood 1985; 65 (4): 823-831, Br.J.Haematol 1986; 63 (4): 681-691), thereby activate platelet, therefore, vWF is that collagen protein activates a hematoblastic key factor under the high shear stress.Have literature research to show, under high shear stress, if there is not the function served as bridge of vWF, (Br.J.Haematol 1986 thereby the direct effect of other multiple receptors of collagen protein and platelet surface can't cause enough platelet to gather the initiation thrombosis; 63 (4): 681-691).
The effect of vWF in the impaired agglutination of arteries is extremely important, people such as Giddings studied pig strength aortic sac expansion impaired after, injured part vWF expresses time dependent relation (Arteriosclerosis, Thrombosis, and Vascular Biology, 1997:17:1872-1878), found that operation is after 10 minutes, in the adherent platelet of injured blood vessel local surfaces, just can detect vWF (not having vWF in the normal pig strength arteries), from perform the operation back 30 minutes to 7 days during this period of time in, can detect the equally distributed vWF of one deck at injured vascular inner surface, this result proves that vascular injury can induce vWF to express/enrichment at injured vascular site, thereby causes series reaction such as blood coagulation.Anti-vWF antibody A jvW-2 is by blood coagulation and neointimal hyperplasia (Arteriosclerosis after proof can suppress vascular injury in the different animals model, Thrombosis, and Vascular Biology, 2000:20:2303-2308, Arteriosclerosis, Thrombosis, and VascularBiology,--: 2003:1105-1100).
Summary of the invention
In view of occurring the vascular restenosis problem in the support implantation process easily, and implant the mechanism of back blood vessel generation restenosis in conjunction with support, the present invention proposes a kind of anti-vWF associated antibodies and proteic biological peptide blood vessel stent of storing, and this support can effectively be prevented hemostatic tube generation restenosis after the support implant surgery.
Based on technical scheme of the present invention, described biological peptide blood vessel stent is the support of grooving, comprises many group metal ripple bars and metal connecting rod.Wherein, described metal ripple bar undulate, grooving on it is stored active constituents of medicine in this groove; The middle part of described metal connecting rod takes the shape of the letter U or S shape, and its two ends are connected with the bending section of different described metal ripple bars respectively.Wherein metal ripple bar plays the main support blood vessel wall, and connecting rod then can increase the compliance of support.Particularly, described support connects into cylindric forming by many groups metal ripple bar and metal connecting rod, use fore-stock to be held on the carrier by pressure, discharge by the sacculus pressurization after being transported to diseased region, strut blood vessel and support blood vessels and do not make its elastical retraction, carrier is then recalled and is finished the entire bracket implantation process.
On active pharmaceutical ingredient, it is the polypeptide of action target spot that the present invention filters out with the vWFA1/A3 territory from the phage polypeptide storehouse, drug stent polymer support commonly used before obstructed the looking over so as to check, directly this class polypeptide is uploaded on the metal rack of surface groove or perforate, after support was implanted, these polypeptide are discharged into the injured vessel wall place rapidly, and were saturated rapidly at injured vascular site, stop exposed collagen protein by vWF to platelet activation, thereby suppress the thrombosis and the restenosis in later stage.
Particularly, the described active constituents of medicine that adopts in technical solution of the present invention can be anti-vWF associated antibodies and/or protein polypeptide, this antibody or albumen are selected from one or more following anti-vWF associated antibodies or albumen: AJvW-2 resists-(human vWF A1 territory) monoclonal antibody (Arteriosclerosis, Thrombosis, and Vascular Biology, 2000:20:2303-2308, Arteriosclerosis, Thrombosis, and Vascular Biology,--: 2003:1105-1100), AJW200 (Contribution of von Willebrand factor to thrombus formation on neointimaof rabbit stenotic iliac artery under high blood-flow velocity.Yamashita A, Asada Y, et al.Arterioscler Thromb Vasc Biol.2003 Jun 1; 23 (6): 1105-10.Epub2003 May 15.), 82D6A3 is anti--(human vWF A3 territory) monoclonal antibody (A consensustetrapeptide selected by phage display adopts the conformation of a dominantdiscontinuous epitope of a monoclonal anti-VWF antibody that inhibits the vonWillebrand factor-collagen interaction.J Biol Chem.2003 Sep 26; 37815-21.Epub 2003 Jul 10), mAb LJ-C3, mAb NMC-4 (anti-A1 territory), mAbMR5 (Identification of domains responsible for von Willebrand factor type VIcollagen interaction mediating platelet adhesion under high flow.Mazzucato M 278 (39):, Spessotto P, et al.J Biol Chem.1999 Jan 29; 274 (5): 3033-41.), ALX-0081 (Ablynx biopharmaceutical company), aurin tricarboxyli acid (ATA) (ATA), orotic acid Saratin; This protein polypeptide has the anti-vWF associated protein of following peptide sequence: GDCFFGFLNSPWRVC (L15G8), RSSYWVYSPWRFISR (L15C5), CMTSPWRC (C6H5), CRTSPWRC (C6G12), CYRSPWRC (C6A12) for one or more.
The title of above-mentioned anti-vWF associated antibodies, for example AJvW-2, AJW200 are the anti-vWF associated antibodies of wide coverage on the relevant speciality document of this area, and its manufacture method can be known by the pertinent literature retrieval.The commercial anti-vWF antibody (as article No. being: HPA001815, HPA002082 and F3520 etc.) that provides of company such as Sigma-aldrich can be used on the support of the present invention in addition.The title of anti-vWF associated protein, for example GDCFFGFLNSPWRVC (L15G8) is the amino acid polypeptide sequence of shorthand, is those skilled in the art's title or code names sanctified by usage to this sequence in the bracket thereafter.Usually can synthesize the polypeptide protein of corresponding sequence according to this sequence.
In technical scheme of the present invention, because the particularity of polypeptide drugs, drug stent polymer support commonly used is inapplicable to the present invention.Common drug stent generally comprises the medicine storage layer of outermost polymer release-control layer and internal layer outside its metal rack, reach the effect of inhibition vascellum endometrial hyperplasia by the rate of release of medicine on the controlled-release function control support of polymer.And antibody/polypeptide can not pass through the polymer controls rate of release because molecular weight ratio is bigger.The present long-term existence in vivo of the non-degradation-type polymer support of drug stent in addition under a cloudly causes allergy and inflammatory reaction, may be to cause the reason that thrombosis generates.That antibody is grafted to rack surface by chemical mode is different with the Genous support of being introduced in the background technology, and the present invention is directly uploaded to the method for polypeptide with physics in the groove of being opened on the ripple bar of support.After this was uploaded mode and can make support implant into body blood vessel, polypeptide was wherein discharged rapidly.This mode has two advantages at least, and the one, polypeptide can discharge rapidly and be penetrated into support and near the vascular tissue of support, can more effectively play a role, and unlike the Genous support, only play a role at rack surface.This method another one advantage is to have exempted loaded down with trivial details chemical graft step, and this can preserve polypeptide active to greatest extent, and minimizing polypeptide raw material is in the waste in this step of chemical graft, and the simplification production technology.Also has non-degradable.
In the selection about the antibody that adopted and/or polypeptide, the polypeptide that the present invention selects for use has the advantage that specificity is good and affinity is high, and is littler than general chemical side effects of pharmaceutical drugs.Compare with commonly used antibody fragment or antibody, polypeptide has also that immunogenicity is low, and toxicity is low, stable high advantage.And polypeptide screens and manufacturing cycle is shorter relatively, does not need to consider peopleization or humanization problem, and the manpower and financial resources of the required input of later stage large-scale production also is significantly less than antibody fragment.Though in general the affinity of polypeptide and its target spot effect comes highly not as antibody, in screening process, pass through the method in repeatedly elutriation and foundation sudden change storehouse, also can obtain the polypeptide of high-affinity.And; with compare at the antiplatelet drug of platelet surface receptor; polypeptide advantage at the vWF target spot is that it only suppresses vascular injury place platelet activation, can not produce any influence to normal or the activated platelet of other physiology, thereby does not have and cause hemorrhage side effect.
Description of drawings
Fig. 1 is the overall structure sketch map of the embodiment of the invention 1 described biological peptide blood vessel stent;
Fig. 2 is the metal ripple bar sectional view in the embodiment of the invention 1 described biological peptide blood vessel stent.
The specific embodiment
Further specify the present invention below by embodiment, but these embodiment do not constitute any restriction to the present invention.
The structure of biological peptide blood vessel stent
Present embodiment provides the example of a biological peptide blood vessel stent, and referring to Fig. 1, it is the overall structure sketch map of biological peptide blood vessel stent.Biological peptide blood vessel stent 1 of the present invention is the support of grooving, and it comprises many group metal ripple bars 11 and metal connecting rod 12,12 '.Wherein, described metal ripple bar 11 undulates have dug groove on it.Described metal ripple bar 11 comprises grooving position and grooving position not, stores active constituents of medicine in the groove at grooving position.Described metal connecting rod 12,12 ' middle part take the shape of the letter U respectively and S shape, and as shown in the figure, the middle part of metal connecting rod 12 is a U-shaped, and the middle part of metal connecting rod 12 ' is a S shape, and its two ends are connected with the bending section of different metal ripple bar respectively.
The cross sectional representation at above-mentioned grooving position sees also Fig. 2, and as shown in the figure, groove has been dug on the surface of metal ripple bar 11, storage active constituents of medicine 13 in this groove.
Embodiment 2
In biological peptide blood vessel stent, load active pharmaceutical ingredient
Present embodiment provides an example that is written into the polypeptide drug active component on intravascular stent, and the intravascular stent that is adopted is as described in the embodiment 1.Described pharmaceutically active ingredient is that to filter out with the vWFA1/A3 territory from the phage polypeptide storehouse be the polypeptide of action target spot, and it is selected from one or more anti-vWF associated protein with following peptide sequence: GDCFFGFLNSPWRVC (L15G8), RSSYWVYSPWRFISR (L15C5), CMTSPWRC (C6H5), CRTSPWRC (C6G12), CYRSPWRC (C6A12).The obstructed preceding drug stent polymer support commonly used of looking over so as to check of described polypeptide uploads on the support, but directly this class polypeptide is uploaded in the groove of being opened on the ripple bar of metal rack, implant these polypeptide of back and can be discharged into the injured vessel wall place rapidly to guarantee support, saturated rapidly at injured vascular site, stop exposed collagen protein by vWF to platelet activation, thereby suppress the thrombosis and the restenosis in later stage.In the present embodiment, this polypeptide protein antibody load mode is accurately to locate drop, directly the solution liquid of the aforementioned polypeptides class material mode by micro-drop is directly dripped in the groove of being opened on metal ripple bar 11 as shown in Figure 2, the polypeptide solution utilization rate is very high under this load mode.
With reference to metal ripple bar sectional view shown in Figure 2, drop peptide C MTSPWRC (C6H5) in the grooving position 111 of metal ripple bar 11, described CMTSPWRC (C6H5) is dissolved in the phosphate buffered solution.This phosphate buffer can pass through 0.2mol/L NaH
2PO
4Solution 19ml and 0.2mol/LNa
2HPO
4Solution 81ml mixes and prepares.Concentration after CMTSPWRC (C6H5) dissolving is 1-100ug/ml, with this polypeptide solution by micro-drop in cradling piece grooving position 111, promptly get CMTSPWRC (C6H5) polypeptide antibody support behind the vacuum analysis.
Embodiment 3
In biological peptide blood vessel stent, load active pharmaceutical ingredient
Present embodiment provides another example that is written into anti-vWF associated antibodies or protein medicaments active component on intravascular stent, and the intravascular stent that is adopted is as described in the embodiment 1.The screening of described active component and load mode are identical with embodiment 2.
With reference to metal ripple bar sectional view shown in Figure 2, drop is selected from one or more anti-vWF associated antibodies or albumen: AJvW-2 (anti--(human vWF A1 territory) monoclonal antibody), AJW200,82D6A3 (resisting-(human vWF A3 territory) monoclonal antibody), mAb LJ-C3, mAb NMC-4 (anti A1 domain), mAb MR5, ALX-0081, aurin tricarboxyli acid (ATA) (ATA), orotic acid the grooving position 111 of metal ripple bar 11 in.Described 82D6A3 is dissolved in the Tris buffer solution.This phosphate buffer can be dissolved in the 1000ml distilled water by 8g NaCl, 0.2g KCl and 3g Tri and mix, and regulates pH to 7.2 promptly.Concentration after the 82D6A3 dissolving is 1-10ug/ml, with this antibody-solutions by micro-drop in cradling piece grooving position 111, promptly get 82D6A3 polypeptide antibody support behind the vacuum analysis.
Claims (5)
1. a biological peptide blood vessel stent is characterized in that, described support is the grooving support, and it is made up of many groups metal ripple bar and metal connecting rod;
Described metal ripple bar undulate, grooving on it is stored active constituents of medicine in this groove;
The middle part of described metal connecting rod takes the shape of the letter U or S shape, and its two ends are connected with the bending section of different described metal ripple bar respectively.
2. biological peptide blood vessel stent according to claim 1, it is characterized in that, described active constituents of medicine is anti-vWF associated antibodies or albumen, is selected from one or more following antibody: AJvW-2, AJW200,82D6A3, mAb LJ-C3, mAb NMC-4, mAb MR5, ALX-0081, aurin tricarboxyli acid (ATA), orotic acid.
3. biological peptide blood vessel stent according to claim 2 is characterized in that, the metal ripple bar surface trough of belt in the described support, and described anti-vWF associated antibodies is to be stated from the physics mode in the described groove, and the mode that this physics is uploaded is micro-drop.
4. biological peptide blood vessel stent according to claim 1, it is characterized in that, described active constituents of medicine is anti-vWF associated protein, is selected from the albumen that one or more have following peptide sequence: GDCFFGFLNSPWRVC, RSSYWVYSPWRFISR, CMTSPWRC, CRTSPWRC, CYRSPWRC.
5. biological peptide blood vessel stent according to claim 4 is characterized in that, the metal ripple bar surface trough of belt in the described support, and described anti-vWF associated protein is to be stated from the physics mode in the described groove, and the mode that this physics is uploaded is micro-drop.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910045840 CN101785718A (en) | 2009-01-23 | 2009-01-23 | Biological peptide blood vessel stent |
| PCT/CN2010/070321 WO2010083770A1 (en) | 2009-01-23 | 2010-01-22 | Vascular stent with biological polypeptides |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910045840 CN101785718A (en) | 2009-01-23 | 2009-01-23 | Biological peptide blood vessel stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101785718A true CN101785718A (en) | 2010-07-28 |
Family
ID=42355556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910045840 Pending CN101785718A (en) | 2009-01-23 | 2009-01-23 | Biological peptide blood vessel stent |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101785718A (en) |
| WO (1) | WO2010083770A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012022400A1 (en) * | 2012-11-16 | 2014-05-22 | Bentley Innomed Gmbh | Temporary stent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100471470C (en) * | 2005-07-08 | 2009-03-25 | 东南大学 | Microporous structure blood vessel stent |
| US20070112421A1 (en) * | 2005-11-14 | 2007-05-17 | O'brien Barry | Medical device with a grooved surface |
| CN2920185Y (en) * | 2006-06-01 | 2007-07-11 | 天津市凯迪亚医疗器械有限公司 | Micro-porous coronary stent |
| CN201019862Y (en) * | 2007-04-06 | 2008-02-13 | 微创医疗器械(上海)有限公司 | Blood vessel supporting with medicament carrying groove |
| CN101313873B (en) * | 2007-05-31 | 2011-03-23 | 乐普（北京）医疗器械股份有限公司 | Biology polypeptide medicament blood vessel bracket and preparation method thereof |
-
2009
- 2009-01-23 CN CN 200910045840 patent/CN101785718A/en active Pending
-
2010
- 2010-01-22 WO PCT/CN2010/070321 patent/WO2010083770A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010083770A1 (en) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stowell et al. | Quickening: Translational design of resorbable synthetic vascular grafts | |
| JP5876173B2 (en) | Method for capturing progenitor endothelial cells using a drug-eluting implantable medical device | |
| Jaganathan et al. | Biomaterials in cardiovascular research: applications and clinical implications | |
| Anderson | Biological responses to materials | |
| US7172758B2 (en) | Endothelialization of vascular surfaces | |
| CN101309653B (en) | Progenitor endothelial cell capturing with drug eluting implantable medical device | |
| US20160081797A1 (en) | Progenitor endothelial cell capturing with a drug eluting implantable medical device | |
| Wolf et al. | Predicting in vivo responses to biomaterials via combined in vitro and in silico analysis | |
| US8414873B2 (en) | Blood vessel stent of amidoglucosan polysaccharide loaded with CD133 antibody and its preparation method | |
| CN101548916B (en) | A medical equipment carrying extracellular matrix and its production method | |
| JP2003526477A (en) | Coating that promotes endothelial cell adhesion | |
| EP3229852B1 (en) | ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONS | |
| Luo et al. | Layer‐by‐layer assembly of chitosan and platelet monoclonal antibody to improve biocompatibility and release character of PLLA coated stent | |
| Dukkipati et al. | Biological Grafts for Hemodialysis Access: Historical Lessons, State‐of‐the‐Art and Future Directions | |
| Anderson et al. | Perspectives on the inflammatory, healing, and foreign body responses to biomaterials and medical devices | |
| Liu et al. | Neointima formation on vascular elastic laminae and collagen matrices scaffolds implanted in the rat aortae | |
| Boire et al. | Biomaterial‐based approaches to address vein graft and hemodialysis access failures | |
| CN101785718A (en) | Biological peptide blood vessel stent | |
| Spadaccio et al. | CURRENT DEVELOPMENTS IN DRUG ELUTING DEVICES: Introductory Editorial: drug-eluting stents or drug-eluting grafts? Insights from proteomic analysis | |
| Ramesh et al. | Crosslinked acellular saphenous vein for small-diameter vascular graft | |
| Galloni et al. | Carbon-coated stents implanted in porcine iliac and renal arteries: histologic and histomorphometric study | |
| JP5828531B2 (en) | Cell specific peptides and uses thereof | |
| JP5664992B2 (en) | Cell specific peptides and uses thereof | |
| Jeong et al. | Biofunctionalized Electrospun Vascular Scaffolds for Enhanced Antithrombotic Properties and In Situ Endothelialization | |
| CN201200505Y (en) | Intravascular stent for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100728 |